| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diet | 24 | 2023 | 390 | 3.110 |
Why?
|
| Dietary Supplements | 14 | 2023 | 187 | 2.700 |
Why?
|
| Energy Intake | 15 | 2024 | 128 | 1.980 |
Why?
|
| Models, Statistical | 9 | 2016 | 180 | 1.780 |
Why?
|
| Nutrition Assessment | 9 | 2019 | 54 | 1.720 |
Why?
|
| Hypoalbuminemia | 2 | 2024 | 13 | 1.510 |
Why?
|
| Neoplasms | 9 | 2024 | 762 | 1.450 |
Why?
|
| Humans | 128 | 2024 | 32814 | 1.330 |
Why?
|
| Vitamin D Deficiency | 7 | 2023 | 91 | 1.270 |
Why?
|
| Nutrition Surveys | 14 | 2023 | 150 | 1.260 |
Why?
|
| Female | 97 | 2024 | 20271 | 1.240 |
Why?
|
| Nutritional Status | 4 | 2024 | 78 | 1.180 |
Why?
|
| Male | 89 | 2024 | 19650 | 1.120 |
Why?
|
| Population Surveillance | 2 | 2019 | 128 | 1.100 |
Why?
|
| Vitamin D | 12 | 2023 | 189 | 1.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2020 | 265 | 0.990 |
Why?
|
| Aged | 57 | 2024 | 10544 | 0.990 |
Why?
|
| Survivors | 8 | 2021 | 168 | 0.970 |
Why?
|
| United States | 31 | 2024 | 4109 | 0.920 |
Why?
|
| Body Mass Index | 9 | 2024 | 908 | 0.920 |
Why?
|
| Adult | 48 | 2024 | 9569 | 0.910 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 384 | 0.890 |
Why?
|
| Diet Surveys | 11 | 2020 | 55 | 0.880 |
Why?
|
| Energy Metabolism | 8 | 2024 | 155 | 0.870 |
Why?
|
| Vitamins | 10 | 2023 | 73 | 0.830 |
Why?
|
| Nutrition Policy | 6 | 2020 | 35 | 0.830 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2020 | 37 | 0.760 |
Why?
|
| Middle Aged | 44 | 2024 | 12133 | 0.750 |
Why?
|
| Food | 3 | 2020 | 42 | 0.740 |
Why?
|
| Colorectal Neoplasms | 5 | 2021 | 222 | 0.730 |
Why?
|
| Nutritional Requirements | 6 | 2021 | 16 | 0.730 |
Why?
|
| Adolescent | 19 | 2024 | 3640 | 0.720 |
Why?
|
| Micronutrients | 5 | 2023 | 20 | 0.720 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 3 | 2020 | 3 | 0.710 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 457 | 0.680 |
Why?
|
| Yoga | 5 | 2023 | 52 | 0.670 |
Why?
|
| Eating | 5 | 2019 | 74 | 0.660 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2020 | 203 | 0.640 |
Why?
|
| Child | 15 | 2024 | 2478 | 0.640 |
Why?
|
| Cholesterol, LDL | 2 | 2020 | 171 | 0.630 |
Why?
|
| Breast Neoplasms | 5 | 2023 | 754 | 0.620 |
Why?
|
| Follow-Up Studies | 10 | 2024 | 2285 | 0.610 |
Why?
|
| Biomedical Research | 3 | 2018 | 171 | 0.610 |
Why?
|
| Food Supply | 5 | 2020 | 67 | 0.600 |
Why?
|
| Child, Preschool | 12 | 2024 | 1282 | 0.600 |
Why?
|
| Dietetics | 2 | 2018 | 4 | 0.600 |
Why?
|
| Statistical Distributions | 2 | 2010 | 5 | 0.590 |
Why?
|
| Papillomavirus Vaccines | 1 | 2019 | 44 | 0.580 |
Why?
|
| Patient Compliance | 3 | 2018 | 218 | 0.580 |
Why?
|
| Nutrition Disorders | 1 | 2018 | 12 | 0.580 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 68 | 0.570 |
Why?
|
| Reproducibility of Results | 10 | 2023 | 767 | 0.570 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2018 | 18 | 0.560 |
Why?
|
| Sodium, Dietary | 1 | 2018 | 23 | 0.550 |
Why?
|
| Cross-Sectional Studies | 18 | 2020 | 1572 | 0.550 |
Why?
|
| Vaccination | 1 | 2019 | 146 | 0.550 |
Why?
|
| African Americans | 7 | 2017 | 1424 | 0.550 |
Why?
|
| Prognosis | 8 | 2024 | 1545 | 0.550 |
Why?
|
| Health Education | 2 | 2020 | 162 | 0.530 |
Why?
|
| Research Design | 2 | 2019 | 332 | 0.520 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 83 | 0.520 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 412 | 0.510 |
Why?
|
| Health | 1 | 2016 | 16 | 0.500 |
Why?
|
| Survival Rate | 6 | 2024 | 894 | 0.480 |
Why?
|
| Young Adult | 14 | 2023 | 2734 | 0.480 |
Why?
|
| Health Promotion | 3 | 2016 | 255 | 0.470 |
Why?
|
| Aged, 80 and over | 19 | 2020 | 4034 | 0.460 |
Why?
|
| Geriatric Assessment | 9 | 2020 | 388 | 0.460 |
Why?
|
| Telemedicine | 4 | 2023 | 117 | 0.430 |
Why?
|
| Infant | 7 | 2024 | 1083 | 0.420 |
Why?
|
| Head and Neck Neoplasms | 4 | 2016 | 134 | 0.420 |
Why?
|
| Rural Population | 7 | 2020 | 286 | 0.420 |
Why?
|
| Prospective Studies | 16 | 2024 | 2329 | 0.410 |
Why?
|
| Colonoscopy | 3 | 2012 | 45 | 0.400 |
Why?
|
| Self Disclosure | 3 | 2015 | 22 | 0.400 |
Why?
|
| Epidemiologic Measurements | 1 | 2013 | 2 | 0.400 |
Why?
|
| Retrospective Studies | 11 | 2024 | 3705 | 0.400 |
Why?
|
| Exercise | 4 | 2019 | 679 | 0.390 |
Why?
|
| Mass Screening | 2 | 2012 | 268 | 0.390 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2015 | 19 | 0.390 |
Why?
|
| Interviews as Topic | 5 | 2014 | 272 | 0.390 |
Why?
|
| Hypertension | 2 | 2018 | 976 | 0.390 |
Why?
|
| Medicaid | 2 | 2012 | 99 | 0.380 |
Why?
|
| Feeding Behavior | 4 | 2020 | 158 | 0.380 |
Why?
|
| Cohort Studies | 10 | 2024 | 1844 | 0.380 |
Why?
|
| Depression | 4 | 2023 | 448 | 0.370 |
Why?
|
| Prostatic Neoplasms | 5 | 2020 | 476 | 0.370 |
Why?
|
| Risk Factors | 17 | 2020 | 3976 | 0.350 |
Why?
|
| Insurance Coverage | 1 | 2012 | 80 | 0.350 |
Why?
|
| Diet Records | 6 | 2019 | 32 | 0.350 |
Why?
|
| Trace Elements | 2 | 2023 | 7 | 0.340 |
Why?
|
| Data Interpretation, Statistical | 3 | 2018 | 114 | 0.330 |
Why?
|
| Animals | 19 | 2024 | 7570 | 0.330 |
Why?
|
| Mental Recall | 10 | 2019 | 51 | 0.330 |
Why?
|
| Pilot Projects | 12 | 2023 | 565 | 0.320 |
Why?
|
| Models, Biological | 2 | 2009 | 392 | 0.320 |
Why?
|
| Social Class | 2 | 2007 | 93 | 0.320 |
Why?
|
| Meditation | 3 | 2023 | 23 | 0.320 |
Why?
|
| Cholecalciferol | 2 | 2023 | 22 | 0.310 |
Why?
|
| Risk | 2 | 2009 | 315 | 0.310 |
Why?
|
| Vegetables | 4 | 2017 | 39 | 0.310 |
Why?
|
| Registries | 4 | 2019 | 315 | 0.310 |
Why?
|
| European Continental Ancestry Group | 8 | 2017 | 1163 | 0.300 |
Why?
|
| Age Factors | 7 | 2024 | 1197 | 0.300 |
Why?
|
| Biometry | 3 | 2016 | 13 | 0.300 |
Why?
|
| Smoking | 5 | 2016 | 531 | 0.300 |
Why?
|
| Sex Factors | 6 | 2024 | 676 | 0.300 |
Why?
|
| Socioeconomic Factors | 5 | 2018 | 436 | 0.300 |
Why?
|
| Muscle Strength | 3 | 2023 | 157 | 0.300 |
Why?
|
| Brain Ischemia | 1 | 2009 | 147 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 949 | 0.280 |
Why?
|
| Dietary Carbohydrates | 2 | 2019 | 23 | 0.270 |
Why?
|
| Dietary Fats | 2 | 2006 | 109 | 0.260 |
Why?
|
| Circadian Rhythm | 1 | 2007 | 45 | 0.260 |
Why?
|
| Brain Injuries | 2 | 2018 | 91 | 0.260 |
Why?
|
| Brain | 3 | 2023 | 946 | 0.250 |
Why?
|
| Mobility Limitation | 4 | 2017 | 220 | 0.240 |
Why?
|
| Postmenopause | 3 | 2024 | 427 | 0.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2014 | 1462 | 0.230 |
Why?
|
| Mammary Glands, Animal | 3 | 2016 | 64 | 0.230 |
Why?
|
| Patient Participation | 2 | 2019 | 87 | 0.230 |
Why?
|
| Abdominal Injuries | 1 | 2005 | 31 | 0.230 |
Why?
|
| Genital Neoplasms, Female | 2 | 2023 | 26 | 0.230 |
Why?
|
| Patient Admission | 1 | 2005 | 59 | 0.230 |
Why?
|
| Pelvis | 1 | 2005 | 64 | 0.230 |
Why?
|
| Telephone | 2 | 2023 | 58 | 0.230 |
Why?
|
| Double-Blind Method | 2 | 2023 | 525 | 0.220 |
Why?
|
| Weightlessness | 1 | 2024 | 9 | 0.220 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2005 | 87 | 0.220 |
Why?
|
| Space Flight | 1 | 2024 | 23 | 0.220 |
Why?
|
| Macaca mulatta | 6 | 2023 | 318 | 0.220 |
Why?
|
| Analysis of Variance | 4 | 2018 | 459 | 0.220 |
Why?
|
| Thoracic Vertebrae | 1 | 2024 | 44 | 0.220 |
Why?
|
| Serum Albumin | 1 | 2024 | 57 | 0.220 |
Why?
|
| Muscular Atrophy | 1 | 2024 | 76 | 0.210 |
Why?
|
| Acute Radiation Syndrome | 1 | 2023 | 4 | 0.210 |
Why?
|
| Feasibility Studies | 7 | 2023 | 308 | 0.210 |
Why?
|
| Lumbar Vertebrae | 1 | 2024 | 110 | 0.210 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2023 | 15 | 0.210 |
Why?
|
| Parathyroid Hormone | 3 | 2012 | 47 | 0.210 |
Why?
|
| Craniocerebral Trauma | 2 | 2015 | 58 | 0.210 |
Why?
|
| Health Personnel | 2 | 2017 | 130 | 0.210 |
Why?
|
| Cognition Disorders | 3 | 2012 | 370 | 0.200 |
Why?
|
| Minerals | 2 | 2020 | 15 | 0.200 |
Why?
|
| Sex Characteristics | 1 | 2024 | 172 | 0.200 |
Why?
|
| Overweight | 2 | 2020 | 263 | 0.200 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2024 | 70 | 0.200 |
Why?
|
| Vitis | 1 | 2023 | 13 | 0.200 |
Why?
|
| Cardiovascular Diseases | 4 | 2016 | 1140 | 0.200 |
Why?
|
| Water | 1 | 2023 | 61 | 0.200 |
Why?
|
| Computer Simulation | 2 | 2016 | 223 | 0.190 |
Why?
|
| Geriatrics | 2 | 2016 | 85 | 0.190 |
Why?
|
| Muscles | 1 | 2023 | 63 | 0.190 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 599 | 0.190 |
Why?
|
| Paclitaxel | 2 | 2024 | 67 | 0.190 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 429 | 0.190 |
Why?
|
| Physical Therapy Modalities | 1 | 2023 | 67 | 0.190 |
Why?
|
| Lymphocytes | 1 | 2022 | 59 | 0.190 |
Why?
|
| Soybean Proteins | 2 | 2016 | 77 | 0.190 |
Why?
|
| Anxiety | 1 | 2023 | 195 | 0.190 |
Why?
|
| Obesity | 5 | 2021 | 1152 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 532 | 0.180 |
Why?
|
| Health Expenditures | 1 | 2002 | 68 | 0.180 |
Why?
|
| Physical Examination | 2 | 2019 | 89 | 0.180 |
Why?
|
| MicroRNAs | 1 | 2024 | 188 | 0.180 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2018 | 36 | 0.180 |
Why?
|
| Incidence | 5 | 2017 | 1239 | 0.170 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2024 | 192 | 0.170 |
Why?
|
| Physical Fitness | 2 | 2012 | 133 | 0.170 |
Why?
|
| Body Composition | 3 | 2020 | 388 | 0.170 |
Why?
|
| Child Nutritional Physiological Phenomena | 2 | 2018 | 7 | 0.170 |
Why?
|
| Postural Balance | 1 | 2023 | 180 | 0.170 |
Why?
|
| Dietary Fiber | 2 | 2013 | 20 | 0.170 |
Why?
|
| Isoflavones | 2 | 2013 | 79 | 0.170 |
Why?
|
| Quality of Life | 5 | 2023 | 962 | 0.160 |
Why?
|
| Diet, Fat-Restricted | 2 | 2014 | 31 | 0.160 |
Why?
|
| Mental Health | 3 | 2016 | 128 | 0.160 |
Why?
|
| Sensitivity and Specificity | 6 | 2020 | 576 | 0.160 |
Why?
|
| Nuts | 1 | 2020 | 5 | 0.160 |
Why?
|
| Food Analysis | 1 | 2020 | 4 | 0.160 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 524 | 0.160 |
Why?
|
| Treatment Outcome | 7 | 2018 | 3441 | 0.160 |
Why?
|
| Poultry Products | 1 | 2020 | 13 | 0.160 |
Why?
|
| Chickens | 1 | 2020 | 35 | 0.160 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2022 | 48 | 0.160 |
Why?
|
| Gene Expression | 2 | 2018 | 334 | 0.160 |
Why?
|
| Pennsylvania | 6 | 2017 | 86 | 0.160 |
Why?
|
| Patient Care Management | 2 | 2016 | 18 | 0.160 |
Why?
|
| Tennessee | 6 | 2017 | 107 | 0.160 |
Why?
|
| Reference Values | 2 | 2018 | 238 | 0.160 |
Why?
|
| Cell Membrane | 1 | 2020 | 96 | 0.160 |
Why?
|
| Bone Marrow | 1 | 2020 | 72 | 0.150 |
Why?
|
| Needs Assessment | 1 | 2020 | 75 | 0.150 |
Why?
|
| Patients | 2 | 2017 | 48 | 0.150 |
Why?
|
| Psychometrics | 2 | 2018 | 137 | 0.150 |
Why?
|
| Cervix Uteri | 1 | 2019 | 26 | 0.150 |
Why?
|
| DNA Damage | 2 | 2018 | 93 | 0.150 |
Why?
|
| Risk Assessment | 3 | 2018 | 1461 | 0.150 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 252 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 95 | 0.150 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 80 | 0.150 |
Why?
|
| Models, Anatomic | 1 | 2019 | 39 | 0.150 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2020 | 52 | 0.150 |
Why?
|
| Obstetrics | 1 | 2019 | 28 | 0.150 |
Why?
|
| Logistic Models | 5 | 2011 | 783 | 0.150 |
Why?
|
| Urban Population | 2 | 2017 | 93 | 0.150 |
Why?
|
| Independent Living | 2 | 2017 | 105 | 0.150 |
Why?
|
| Regression Analysis | 3 | 2009 | 288 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2024 | 1307 | 0.150 |
Why?
|
| Beverages | 2 | 2015 | 19 | 0.150 |
Why?
|
| Epidemiologic Research Design | 1 | 2018 | 5 | 0.150 |
Why?
|
| Mammary Glands, Human | 1 | 2018 | 14 | 0.150 |
Why?
|
| Cranial Irradiation | 2 | 2017 | 93 | 0.140 |
Why?
|
| Air Pollution | 1 | 2018 | 17 | 0.140 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 24 | 0.140 |
Why?
|
| Environmental Monitoring | 1 | 2018 | 27 | 0.140 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 68 | 0.140 |
Why?
|
| Fibronectins | 1 | 2018 | 37 | 0.140 |
Why?
|
| Diet, Mediterranean | 1 | 2018 | 31 | 0.140 |
Why?
|
| Brain Neoplasms | 3 | 2013 | 647 | 0.140 |
Why?
|
| Carboplatin | 1 | 2018 | 51 | 0.140 |
Why?
|
| Health Status | 4 | 2015 | 402 | 0.140 |
Why?
|
| Blood Cells | 1 | 2018 | 9 | 0.140 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 62 | 0.140 |
Why?
|
| Income | 1 | 2018 | 67 | 0.140 |
Why?
|
| Health Surveys | 3 | 2013 | 200 | 0.140 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 98 | 0.140 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 265 | 0.140 |
Why?
|
| Environmental Exposure | 1 | 2018 | 89 | 0.140 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 95 | 0.140 |
Why?
|
| Gardening | 1 | 2017 | 2 | 0.140 |
Why?
|
| Poverty | 3 | 2020 | 116 | 0.130 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 258 | 0.130 |
Why?
|
| Blood Pressure Determination | 1 | 2018 | 102 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 113 | 0.130 |
Why?
|
| Hemorrhage | 2 | 2015 | 107 | 0.130 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 155 | 0.130 |
Why?
|
| Environment | 1 | 2017 | 50 | 0.130 |
Why?
|
| Atherosclerosis | 2 | 2017 | 788 | 0.130 |
Why?
|
| Awareness | 1 | 2017 | 29 | 0.130 |
Why?
|
| Decision Making | 2 | 2012 | 202 | 0.130 |
Why?
|
| Amino Acids | 1 | 2017 | 46 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2017 | 181 | 0.130 |
Why?
|
| Insulin Resistance | 2 | 2011 | 469 | 0.130 |
Why?
|
| Prevalence | 4 | 2020 | 1002 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 50 | 0.130 |
Why?
|
| Cognition | 3 | 2016 | 551 | 0.130 |
Why?
|
| Physician's Role | 1 | 2016 | 39 | 0.120 |
Why?
|
| Extracellular Matrix | 1 | 2018 | 243 | 0.120 |
Why?
|
| Rural Health | 2 | 2007 | 44 | 0.120 |
Why?
|
| Internet | 1 | 2018 | 201 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2017 | 78 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2016 | 53 | 0.120 |
Why?
|
| Body Weight | 4 | 2023 | 301 | 0.120 |
Why?
|
| Sexual Maturation | 1 | 2016 | 25 | 0.120 |
Why?
|
| Kidney | 1 | 2020 | 520 | 0.120 |
Why?
|
| Longitudinal Studies | 5 | 2019 | 779 | 0.120 |
Why?
|
| Epilepsy | 1 | 2017 | 83 | 0.120 |
Why?
|
| Cotinine | 3 | 2015 | 52 | 0.120 |
Why?
|
| Diabetic Angiopathies | 1 | 2016 | 145 | 0.120 |
Why?
|
| Medical Oncology | 1 | 2016 | 92 | 0.120 |
Why?
|
| Residence Characteristics | 1 | 2017 | 197 | 0.120 |
Why?
|
| Homebound Persons | 1 | 2015 | 9 | 0.120 |
Why?
|
| Proportional Hazards Models | 5 | 2018 | 764 | 0.120 |
Why?
|
| Food Services | 1 | 2015 | 20 | 0.120 |
Why?
|
| Time Factors | 6 | 2018 | 2183 | 0.110 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2015 | 10 | 0.110 |
Why?
|
| Wheelchairs | 1 | 2014 | 1 | 0.110 |
Why?
|
| Decontamination | 1 | 2014 | 3 | 0.110 |
Why?
|
| Disinfection | 1 | 2014 | 6 | 0.110 |
Why?
|
| Spinal Cord Injuries | 1 | 2015 | 40 | 0.110 |
Why?
|
| Neuropsychological Tests | 3 | 2012 | 363 | 0.110 |
Why?
|
| Hypotension | 1 | 2015 | 48 | 0.110 |
Why?
|
| Cell Differentiation | 2 | 2016 | 468 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 158 | 0.110 |
Why?
|
| Injury Severity Score | 3 | 2015 | 111 | 0.110 |
Why?
|
| Fruit | 2 | 2012 | 56 | 0.110 |
Why?
|
| Polypharmacy | 1 | 2014 | 17 | 0.110 |
Why?
|
| Caregivers | 1 | 2016 | 121 | 0.110 |
Why?
|
| Disabled Persons | 2 | 2012 | 105 | 0.110 |
Why?
|
| Cross Infection | 1 | 2014 | 56 | 0.110 |
Why?
|
| Probability | 2 | 2005 | 157 | 0.100 |
Why?
|
| Body Size | 2 | 2020 | 34 | 0.100 |
Why?
|
| United States Department of Agriculture | 1 | 2013 | 3 | 0.100 |
Why?
|
| Food Handling | 1 | 2013 | 7 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 162 | 0.100 |
Why?
|
| Motor Activity | 2 | 2013 | 327 | 0.100 |
Why?
|
| Pain, Postoperative | 1 | 2016 | 193 | 0.100 |
Why?
|
| Puberty | 1 | 2013 | 7 | 0.100 |
Why?
|
| Accidental Falls | 1 | 2015 | 221 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 188 | 0.100 |
Why?
|
| Soybeans | 1 | 2013 | 35 | 0.100 |
Why?
|
| Dacarbazine | 1 | 2013 | 29 | 0.100 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 23 | 0.100 |
Why?
|
| Shock | 1 | 2013 | 32 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2013 | 40 | 0.100 |
Why?
|
| Seasons | 3 | 2011 | 89 | 0.100 |
Why?
|
| Models, Psychological | 1 | 2013 | 26 | 0.100 |
Why?
|
| Markov Chains | 1 | 2013 | 32 | 0.100 |
Why?
|
| Indians, North American | 3 | 2007 | 110 | 0.100 |
Why?
|
| Hyperparathyroidism | 1 | 2012 | 9 | 0.100 |
Why?
|
| Affect | 1 | 2013 | 70 | 0.090 |
Why?
|
| Nonverbal Communication | 1 | 2012 | 4 | 0.090 |
Why?
|
| Time | 1 | 2012 | 23 | 0.090 |
Why?
|
| Therapeutic Touch | 2 | 2012 | 9 | 0.090 |
Why?
|
| Hip Fractures | 1 | 2012 | 30 | 0.090 |
Why?
|
| Primates | 2 | 2023 | 116 | 0.090 |
Why?
|
| Empathy | 1 | 2012 | 17 | 0.090 |
Why?
|
| Touch | 1 | 2012 | 38 | 0.090 |
Why?
|
| Autonomic Nervous System | 1 | 2012 | 44 | 0.090 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2012 | 37 | 0.090 |
Why?
|
| Indans | 1 | 2012 | 34 | 0.090 |
Why?
|
| Smoking Cessation | 2 | 2012 | 216 | 0.090 |
Why?
|
| Indiana | 2 | 2022 | 27 | 0.090 |
Why?
|
| Glasgow Coma Scale | 2 | 2015 | 28 | 0.090 |
Why?
|
| Glioblastoma | 1 | 2013 | 157 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 360 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2013 | 160 | 0.090 |
Why?
|
| Language Tests | 1 | 2011 | 5 | 0.090 |
Why?
|
| Intelligence Tests | 1 | 2011 | 9 | 0.090 |
Why?
|
| Piperidines | 1 | 2012 | 120 | 0.090 |
Why?
|
| Monte Carlo Method | 1 | 2010 | 19 | 0.080 |
Why?
|
| Trauma Centers | 2 | 2015 | 86 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 2010 | 9 | 0.080 |
Why?
|
| Likelihood Functions | 1 | 2010 | 48 | 0.080 |
Why?
|
| Calcium, Dietary | 1 | 2010 | 23 | 0.080 |
Why?
|
| Iron, Dietary | 1 | 2010 | 13 | 0.080 |
Why?
|
| Disease Management | 1 | 2011 | 128 | 0.080 |
Why?
|
| Vitamin A | 1 | 2010 | 21 | 0.080 |
Why?
|
| North Carolina | 6 | 2012 | 1546 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 475 | 0.080 |
Why?
|
| Adenoma | 1 | 2011 | 35 | 0.080 |
Why?
|
| Sunscreening Agents | 1 | 2010 | 13 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 74 | 0.080 |
Why?
|
| Biostatistics | 1 | 2010 | 8 | 0.080 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2010 | 1 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 205 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2010 | 20 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2012 | 162 | 0.080 |
Why?
|
| Memory | 1 | 2012 | 191 | 0.080 |
Why?
|
| Cancer Vaccines | 1 | 2010 | 24 | 0.080 |
Why?
|
| Heart Rate | 1 | 2012 | 343 | 0.080 |
Why?
|
| Nutritional Physiological Phenomena | 2 | 2007 | 18 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 34 | 0.080 |
Why?
|
| Algorithms | 2 | 2010 | 511 | 0.080 |
Why?
|
| Patient Selection | 2 | 2012 | 281 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2015 | 828 | 0.080 |
Why?
|
| Aging | 5 | 2017 | 938 | 0.080 |
Why?
|
| Comorbidity | 4 | 2013 | 573 | 0.080 |
Why?
|
| Nutritive Value | 2 | 2020 | 10 | 0.080 |
Why?
|
| Hand Strength | 1 | 2010 | 101 | 0.080 |
Why?
|
| Linear Models | 3 | 2020 | 445 | 0.080 |
Why?
|
| Educational Status | 2 | 2007 | 183 | 0.070 |
Why?
|
| Melanoma | 1 | 2010 | 165 | 0.070 |
Why?
|
| Fibrinogen | 1 | 2008 | 45 | 0.070 |
Why?
|
| Body Water | 2 | 2009 | 8 | 0.070 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 43 | 0.070 |
Why?
|
| Maryland | 2 | 2009 | 28 | 0.070 |
Why?
|
| Walking | 1 | 2010 | 210 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 178 | 0.070 |
Why?
|
| Contraceptives, Oral | 1 | 2008 | 22 | 0.070 |
Why?
|
| Glucose Tolerance Test | 1 | 2008 | 125 | 0.070 |
Why?
|
| Counseling | 2 | 2012 | 98 | 0.070 |
Why?
|
| Hospitalization | 1 | 2011 | 488 | 0.070 |
Why?
|
| Mice | 4 | 2023 | 2512 | 0.070 |
Why?
|
| Deuterium Oxide | 1 | 2007 | 1 | 0.070 |
Why?
|
| Calorimetry | 1 | 2007 | 3 | 0.070 |
Why?
|
| Leukemia | 1 | 2008 | 37 | 0.070 |
Why?
|
| Estrogens | 1 | 2008 | 169 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 300 | 0.070 |
Why?
|
| African Continental Ancestry Group | 3 | 2014 | 363 | 0.070 |
Why?
|
| Macaca fascicularis | 3 | 2016 | 431 | 0.070 |
Why?
|
| Tunica Intima | 1 | 2007 | 57 | 0.070 |
Why?
|
| Carotid Artery, Common | 1 | 2007 | 39 | 0.070 |
Why?
|
| Adenomatous Polyps | 1 | 2007 | 8 | 0.070 |
Why?
|
| Ganglionic Stimulants | 1 | 2007 | 7 | 0.060 |
Why?
|
| Adaptation, Psychological | 1 | 2008 | 138 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2008 | 103 | 0.060 |
Why?
|
| Insulin | 1 | 2008 | 367 | 0.060 |
Why?
|
| Genes, APC | 1 | 2006 | 1 | 0.060 |
Why?
|
| Intestinal Polyps | 1 | 2006 | 4 | 0.060 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2007 | 60 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 682 | 0.060 |
Why?
|
| Running | 1 | 2006 | 19 | 0.060 |
Why?
|
| Carotid Artery Diseases | 1 | 2007 | 116 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2008 | 494 | 0.060 |
Why?
|
| Physical Conditioning, Animal | 1 | 2006 | 35 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2023 | 199 | 0.060 |
Why?
|
| Dietary Sucrose | 1 | 2006 | 11 | 0.060 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2006 | 57 | 0.060 |
Why?
|
| Tobacco Use Disorder | 1 | 2007 | 90 | 0.060 |
Why?
|
| Role | 1 | 2005 | 5 | 0.060 |
Why?
|
| Blood Cell Count | 2 | 2018 | 27 | 0.060 |
Why?
|
| Crack Cocaine | 1 | 2005 | 4 | 0.060 |
Why?
|
| HIV Seropositivity | 1 | 2005 | 14 | 0.060 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2005 | 28 | 0.060 |
Why?
|
| Inflammation | 1 | 2008 | 536 | 0.060 |
Why?
|
| Triglycerides | 2 | 2016 | 228 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 888 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2005 | 96 | 0.060 |
Why?
|
| Nicotine | 1 | 2007 | 177 | 0.050 |
Why?
|
| Cocaine-Related Disorders | 1 | 2005 | 98 | 0.050 |
Why?
|
| Personality Assessment | 1 | 2004 | 9 | 0.050 |
Why?
|
| Social Desirability | 1 | 2004 | 11 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 307 | 0.050 |
Why?
|
| Body Image | 1 | 2004 | 19 | 0.050 |
Why?
|
| Models, Animal | 2 | 2020 | 171 | 0.050 |
Why?
|
| Platinum | 1 | 2024 | 21 | 0.050 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2023 | 4 | 0.050 |
Why?
|
| Organ Size | 1 | 2024 | 219 | 0.050 |
Why?
|
| Independent Practice Associations | 1 | 2003 | 3 | 0.050 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2023 | 31 | 0.050 |
Why?
|
| Ligands | 1 | 2023 | 78 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2003 | 41 | 0.050 |
Why?
|
| Documentation | 1 | 2003 | 47 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2023 | 114 | 0.050 |
Why?
|
| Mortality | 1 | 2024 | 124 | 0.050 |
Why?
|
| Phobic Disorders | 1 | 2023 | 9 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 471 | 0.050 |
Why?
|
| Pain Measurement | 2 | 2016 | 356 | 0.050 |
Why?
|
| Emotions | 1 | 2023 | 59 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 83 | 0.050 |
Why?
|
| Fear | 1 | 2023 | 50 | 0.050 |
Why?
|
| Self Efficacy | 1 | 2023 | 81 | 0.050 |
Why?
|
| Forecasting | 1 | 2023 | 143 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2005 | 490 | 0.050 |
Why?
|
| Demography | 2 | 2016 | 110 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2024 | 349 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 97 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2023 | 138 | 0.040 |
Why?
|
| Life Style | 1 | 2004 | 407 | 0.040 |
Why?
|
| Bacteroides | 1 | 2021 | 8 | 0.040 |
Why?
|
| Prevotella | 1 | 2021 | 8 | 0.040 |
Why?
|
| Monocytes | 1 | 2022 | 130 | 0.040 |
Why?
|
| Lactobacillus | 1 | 2021 | 13 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 43 | 0.040 |
Why?
|
| Morbidity | 2 | 2011 | 101 | 0.040 |
Why?
|
| Pain | 1 | 2023 | 295 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 255 | 0.040 |
Why?
|
| Midwestern United States | 1 | 2020 | 8 | 0.040 |
Why?
|
| Vitamin B 6 | 1 | 2020 | 2 | 0.040 |
Why?
|
| Magnesium | 1 | 2020 | 30 | 0.040 |
Why?
|
| Appalachian Region | 1 | 2020 | 20 | 0.040 |
Why?
|
| Calibration | 1 | 2020 | 28 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 326 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 40 | 0.040 |
Why?
|
| Ethnic Groups | 2 | 2017 | 474 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2020 | 59 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 92 | 0.040 |
Why?
|
| Labor Stage, First | 1 | 2019 | 9 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 168 | 0.040 |
Why?
|
| Fibrosis | 1 | 2020 | 122 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 292 | 0.040 |
Why?
|
| Validation Studies as Topic | 1 | 2018 | 6 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2020 | 147 | 0.040 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2018 | 4 | 0.040 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2019 | 79 | 0.040 |
Why?
|
| Air Pollutants | 1 | 2018 | 23 | 0.040 |
Why?
|
| Haplorhini | 1 | 2018 | 69 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 563 | 0.040 |
Why?
|
| Calcium | 1 | 2020 | 323 | 0.040 |
Why?
|
| Micronucleus Tests | 1 | 2018 | 4 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 23 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2018 | 82 | 0.030 |
Why?
|
| Thorax | 1 | 2018 | 30 | 0.030 |
Why?
|
| Students, Medical | 1 | 2019 | 132 | 0.030 |
Why?
|
| Disease Progression | 2 | 2012 | 594 | 0.030 |
Why?
|
| Lung Injury | 1 | 2018 | 67 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2009 | 185 | 0.030 |
Why?
|
| Oncology Service, Hospital | 1 | 2016 | 4 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 99 | 0.030 |
Why?
|
| Education | 1 | 2016 | 37 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2019 | 338 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 57 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 80 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 117 | 0.030 |
Why?
|
| Neuronal Plasticity | 1 | 2017 | 80 | 0.030 |
Why?
|
| Pregnancy | 1 | 2019 | 981 | 0.030 |
Why?
|
| Phytoestrogens | 1 | 2016 | 22 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 175 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 106 | 0.030 |
Why?
|
| Diet Therapy | 1 | 2015 | 15 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 199 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 154 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2015 | 20 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2016 | 204 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2015 | 195 | 0.030 |
Why?
|
| Data Collection | 1 | 2015 | 185 | 0.030 |
Why?
|
| Curriculum | 1 | 2016 | 211 | 0.030 |
Why?
|
| Canada | 1 | 2014 | 64 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2015 | 84 | 0.030 |
Why?
|
| Public Health | 1 | 2015 | 89 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 497 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2014 | 74 | 0.030 |
Why?
|
| Adiposity | 1 | 2015 | 198 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2014 | 104 | 0.030 |
Why?
|
| Length of Stay | 1 | 2015 | 329 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 100 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 386 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 43 | 0.030 |
Why?
|
| Affective Symptoms | 1 | 2013 | 17 | 0.020 |
Why?
|
| Louisiana | 1 | 2013 | 12 | 0.020 |
Why?
|
| Age Distribution | 1 | 2013 | 201 | 0.020 |
Why?
|
| Medicare | 1 | 2014 | 213 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2015 | 694 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2013 | 65 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 189 | 0.020 |
Why?
|
| Software | 1 | 2013 | 124 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 126 | 0.020 |
Why?
|
| Reading | 1 | 2012 | 5 | 0.020 |
Why?
|
| Love | 1 | 2012 | 4 | 0.020 |
Why?
|
| Relaxation | 1 | 2012 | 9 | 0.020 |
Why?
|
| Respiratory Rate | 1 | 2012 | 13 | 0.020 |
Why?
|
| Patient Preference | 1 | 2012 | 47 | 0.020 |
Why?
|
| Digital Rectal Examination | 1 | 2012 | 10 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 29 | 0.020 |
Why?
|
| Rest | 1 | 2012 | 52 | 0.020 |
Why?
|
| Self Administration | 1 | 2013 | 293 | 0.020 |
Why?
|
| Extremities | 1 | 2012 | 54 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 63 | 0.020 |
Why?
|
| Outpatients | 1 | 2012 | 57 | 0.020 |
Why?
|
| Executive Function | 1 | 2012 | 56 | 0.020 |
Why?
|
| Nursing Assessment | 1 | 2011 | 11 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 186 | 0.020 |
Why?
|
| Cause of Death | 1 | 2012 | 240 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 498 | 0.020 |
Why?
|
| Students | 1 | 2013 | 179 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 245 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2015 | 862 | 0.020 |
Why?
|
| Health Behavior | 1 | 2012 | 234 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 603 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 16 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 245 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 111 | 0.020 |
Why?
|
| CD4-CD8 Ratio | 1 | 2010 | 2 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2010 | 12 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2011 | 238 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2010 | 48 | 0.020 |
Why?
|
| Androgens | 1 | 2010 | 28 | 0.020 |
Why?
|
| Fishes | 1 | 2009 | 6 | 0.020 |
Why?
|
| Mercury | 1 | 2009 | 6 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 175 | 0.020 |
Why?
|
| Physicians | 1 | 2012 | 165 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 467 | 0.020 |
Why?
|
| District of Columbia | 1 | 2009 | 4 | 0.020 |
Why?
|
| Basal Metabolism | 1 | 2009 | 9 | 0.020 |
Why?
|
| Oxygen Isotopes | 1 | 2009 | 7 | 0.020 |
Why?
|
| Deuterium | 1 | 2009 | 9 | 0.020 |
Why?
|
| Sarcoma | 1 | 2010 | 71 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2010 | 453 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2008 | 33 | 0.020 |
Why?
|
| Endometrium | 1 | 2008 | 42 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 94 | 0.020 |
Why?
|
| Random Allocation | 1 | 2008 | 229 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2008 | 34 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 727 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2010 | 217 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 789 | 0.020 |
Why?
|
| Observation | 1 | 2007 | 24 | 0.020 |
Why?
|
| Carotid Artery, Internal | 1 | 2007 | 32 | 0.020 |
Why?
|
| Acute Disease | 1 | 2008 | 259 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2007 | 31 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2007 | 52 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 1012 | 0.020 |
Why?
|
| Corticosterone | 1 | 2006 | 7 | 0.020 |
Why?
|
| Hematocrit | 1 | 2006 | 23 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 271 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 240 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2008 | 226 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2006 | 83 | 0.010 |
Why?
|
| Massachusetts | 1 | 2005 | 26 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 2005 | 125 | 0.010 |
Why?
|
| Vermont | 1 | 2003 | 2 | 0.010 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2003 | 5 | 0.010 |
Why?
|
| Efficiency, Organizational | 1 | 2003 | 19 | 0.010 |
Why?
|
| Reminder Systems | 1 | 2003 | 23 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2003 | 49 | 0.010 |
Why?
|
| Health Services Research | 1 | 2003 | 81 | 0.010 |
Why?
|